UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 182

Sortiert nach

Molecular Mechanisms of the Cardiotoxicity of the Proteasomal-Targeted Drugs Bortezomib and Carfilzomib

Cardiovascular toxicology, 2017-07, Vol.17 (3), p.237-250

2017

Link zum Volltext

Verfügbarkeit prüfen

Mechanisms of Myocyte Cytotoxicity Induced by the Multiple Receptor Tyrosine Kinase Inhibitor Sunitinib

Molecular pharmacology, 2008-12, Vol.74 (6), p.1722-1728

2008

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of Nitrobenzyl Derivatives of Camptothecin as Anti-Cancer Agents and Potential Hypoxia Targeting Prodrugs

Molecules (Basel, Switzerland), 2018-08, Vol.23 (8), p.2041

2018

Link zum Volltext

Verfügbarkeit prüfen

A QSAR study that compares the ability of bisdioxopiperazine analogs of the doxorubicin cardioprotective agent dexrazoxane (ICRF-187) to protect myocytes with DNA topoisomerase II inhibition

Toxicology and applied pharmacology, 2020-07, Vol.399, p.115038, Article 115038

2020

Link zum Volltext

Verfügbarkeit prüfen

Progress curve analysis of the kinetics of slow-binding anticancer drug inhibitors of the 20S proteasome

Archives of biochemistry and biophysics, 2018-02, Vol.639, p.52-58

Hasinoff, Brian B.

2018

Link zum Volltext

Verfügbarkeit prüfen

The use of dexrazoxane for the prevention of anthracycline extravasation injury

Expert opinion on investigational drugs, 2008-02, Vol.17 (2), p.217-223

Hasinoff, Brian B

2008

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy

Toxicology (Amsterdam), 2009-01, Vol.255 (1), p.72-79

2009

Link zum Volltext

Verfügbarkeit prüfen

The cardiotoxicity and myocyte damage caused by small molecule anticancer tyrosine kinase inhibitors is correlated with lack of target specificity

Toxicology and applied pharmacology, 2010-04, Vol.244 (2), p.190-195

Hasinoff, Brian B.

2010

Link zum Volltext

Verfügbarkeit prüfen

The lack of target specificity of small molecule anticancer kinase inhibitors is correlated with their ability to damage myocytes in vitro

Toxicology and applied pharmacology, 2010-12, Vol.249 (2), p.132-139

2010

Link zum Volltext

Verfügbarkeit prüfen

Disulfiram is a slow-binding partial noncompetitive inhibitor of 20S proteasome activity

Archives of biochemistry and biophysics, 2017-11, Vol.633, p.23-28

2017

Link zum Volltext

Verfügbarkeit prüfen

Mechanisms of the Cardiac Myocyte-Damaging Effects of Dasatinib

Cardiovascular toxicology, 2020-08, Vol.20 (4), p.380-389

2020

Link zum Volltext

Verfügbarkeit prüfen

A diazirine-based photoaffinity etoposide probe for labeling topoisomerase II

Bioorganic & medicinal chemistry, 2010-01, Vol.18 (2), p.830-838

2010

Link zum Volltext

Verfügbarkeit prüfen

Mechanisms of Action and Reduced Cardiotoxicity of Pixantrone; a Topoisomerase II Targeting Agent with Cellular Selectivity for the Topoisomerase IIα Isoform

The Journal of pharmacology and experimental therapeutics, 2016-02, Vol.356 (2), p.397

2016

Link zum Volltext

Verfügbarkeit prüfen

The Role of Topoisomerase IIβ in the Mechanisms of Action of the Doxorubicin Cardioprotective Agent Dexrazoxane

Cardiovascular toxicology, 2020-06, Vol.20 (3), p.312-320

2020

Link zum Volltext

Verfügbarkeit prüfen

Myocyte-Damaging Effects and Binding Kinetics of Boronic Acid and Epoxyketone Proteasomal-Targeted Drugs

Cardiovascular toxicology, 2018-12, Vol.18 (6), p.557-568

2018

Link zum Volltext

Verfügbarkeit prüfen

The Myocyte-Damaging Effects of the BCR-ABL1-Targeted Tyrosine Kinase Inhibitors Increase with Potency and Decrease with Specificity

Cardiovascular toxicology, 2017-07, Vol.17 (3), p.297-306

2017

Link zum Volltext

Verfügbarkeit prüfen

Molecular mechanisms of the biological activity of the anticancer drug elesclomol and its complexes with Cu(II), Ni(II) and Pt(II)

Journal of inorganic biochemistry, 2013-09, Vol.126, p.1-6

2013

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3060: Molecular mechanisms of the cardiotoxicity of the proteasomal-targeted anticancer drugs bortezomib and carfilzomib

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.3060-3060

2016

Link zum Volltext

Verfügbarkeit prüfen

Mechanism of the cytotoxicity of the diazoparaquinone antitumor antibiotic kinamycin F

Free radical biology & medicine, 2007-10, Vol.43 (8), p.1132-1144

2007

Link zum Volltext

Verfügbarkeit prüfen

Total Synthesis of Isoprekinamycin: Structural Evidence for Enhanced Diazonium Ion Character and Growth Inhibitory Activity toward Cancer Cells

Organic letters, 2007-07, Vol.9 (15), p.2915-2918

2007

Link zum Volltext

Verfügbarkeit prüfen

Cellular mechanisms of the cytotoxicity of the anticancer drug elesclomol and its complex with Cu(II)

Biochemical pharmacology, 2015-02, Vol.93 (3), p.266-276

2015

Link zum Volltext

Verfügbarkeit prüfen

The dihydroorotase inhibitor 5-aminoorotic acid inhibits the metabolism in the rat of the cardioprotective drug dexrazoxane and its one-ring open metabolites

Drug metabolism and disposition, 2008-09, Vol.36 (9), p.1780

2008

Link zum Volltext

Verfügbarkeit prüfen

Metabolism of the one-ring open metabolites of the cardioprotective drug dexrazoxane to its active metal-chelating form in the rat

Drug metabolism and disposition, 2005-09, Vol.33 (9), p.1367

2005

Link zum Volltext

Verfügbarkeit prüfen

The Metabolites of the Cardioprotective Drug Dexrazoxane Do Not Protect Myocytes from Doxorubicin-Induced Cytotoxicity

Molecular pharmacology, 2003-09, Vol.64 (3), p.670-678

2003

Link zum Volltext

Verfügbarkeit prüfen

The anticancer multi-kinase inhibitor dovitinib also targets topoisomerase I and topoisomerase II

Biochemical pharmacology, 2012-12, Vol.84 (12), p.1617-1626

2012

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 182

Suche als RSS-Feed

Aktive Filter

SpracheEnglisch

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(174)
Mit Volltextzugriff
(169)

Publikationsform

Artikel
(182)

Sprache

Japanisch
(24)
Französisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(135)
Life Sciences & Biomedicine
(131)
Animals
(71)
Pharmacology & Pharmacy
(63)
Biological And Medical Sciences
(56)
Biochemistry & Molecular Biology
(55)
Humans
(47)
Medical Sciences
(43)
Chemistry
(37)
Physical Sciences
(36)
Rats
(35)
Pharmacology. Drug Treatments
(33)
Doxorubicin
(32)
Dexrazoxane
(31)
Kinetics
(31)
Rats, Sprague-Dawley
(29)
Antineoplastic Agents - Pharmacology
(26)
K562 Cells
(26)
Razoxane - Pharmacology
(26)
Topoisomerase Ii Inhibitors
(24)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Molecular Mechanisms of the Cardiotoxicity of the Proteasomal-Targeted Drugs Bortezomib and Carfilzomib

Mechanisms of Myocyte Cytotoxicity Induced by the Multiple Receptor Tyrosine Kinase Inhibitor Sunitinib

Evaluation of Nitrobenzyl Derivatives of Camptothecin as Anti-Cancer Agents and Potential Hypoxia Targeting Prodrugs

A QSAR study that compares the ability of bisdioxopiperazine analogs of the doxorubicin cardioprotective agent dexrazoxane (ICRF-187) to protect myocytes with DNA topoisomerase II inhibition

Progress curve analysis of the kinetics of slow-binding anticancer drug inhibitors of the 20S proteasome

The use of dexrazoxane for the prevention of anthracycline extravasation injury

Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy

The cardiotoxicity and myocyte damage caused by small molecule anticancer tyrosine kinase inhibitors is correlated with lack of target specificity

The lack of target specificity of small molecule anticancer kinase inhibitors is correlated with their ability to damage myocytes in vitro

Disulfiram is a slow-binding partial noncompetitive inhibitor of 20S proteasome activity

Mechanisms of the Cardiac Myocyte-Damaging Effects of Dasatinib

A diazirine-based photoaffinity etoposide probe for labeling topoisomerase II

Mechanisms of Action and Reduced Cardiotoxicity of Pixantrone; a Topoisomerase II Targeting Agent with Cellular Selectivity for the Topoisomerase IIα Isoform

The Role of Topoisomerase IIβ in the Mechanisms of Action of the Doxorubicin Cardioprotective Agent Dexrazoxane

Myocyte-Damaging Effects and Binding Kinetics of Boronic Acid and Epoxyketone Proteasomal-Targeted Drugs

The Myocyte-Damaging Effects of the BCR-ABL1-Targeted Tyrosine Kinase Inhibitors Increase with Potency and Decrease with Specificity

Molecular mechanisms of the biological activity of the anticancer drug elesclomol and its complexes with Cu(II), Ni(II) and Pt(II)

Abstract 3060: Molecular mechanisms of the cardiotoxicity of the proteasomal-targeted anticancer drugs bortezomib and carfilzomib

Mechanism of the cytotoxicity of the diazoparaquinone antitumor antibiotic kinamycin F

Total Synthesis of Isoprekinamycin: Structural Evidence for Enhanced Diazonium Ion Character and Growth Inhibitory Activity toward Cancer Cells

Cellular mechanisms of the cytotoxicity of the anticancer drug elesclomol and its complex with Cu(II)

The dihydroorotase inhibitor 5-aminoorotic acid inhibits the metabolism in the rat of the cardioprotective drug dexrazoxane and its one-ring open metabolites

Metabolism of the one-ring open metabolites of the cardioprotective drug dexrazoxane to its active metal-chelating form in the rat

The Metabolites of the Cardioprotective Drug Dexrazoxane Do Not Protect Myocytes from Doxorubicin-Induced Cytotoxicity

The anticancer multi-kinase inhibitor dovitinib also targets topoisomerase I and topoisomerase II

Aktive Filter

Suchergebnisse filtern